In the hepatological space, both the FDA and EMA have approved Ipsen’s Iqirvo (elafibranor) and Gilead’s Livdelzi (seladelpar), the latter being marketed at Seladelpar Gilead in Europe.

以及治疗原发性胆汁性胆管炎的Iqirvo（elafibranor）等。 抗感染药物 在抗感染领域，2024年获批的新药也为临床治疗提供了有力支持： Exblifep（头孢吡 ...

Salk scientists discover that removing bile acid-creating protein BAAT and adding bile acid UDCA controls tumor growth in mice with liver cancer; UDCA dietary supplements may be quick solution to ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products. Below is a review of novel drug and biological products approved by the Food and Drug ...

Several things can trigger acid reflux or a GERD episode, including some eating habits (like having dinner very late at night) or eating certain foods (like spicy, acidic, or fatty foods).

Essential amino acids are organic compounds that your body needs to function. You can get them from certain foods. Amino acids, often referred to as the building blocks of proteins, are compounds ...

CHOLIC and chenodeoxycholic acids are formed from cholesterol in the liver and are then excreted in the bile to the intestinal tract. There they are broken down to form, for example, deoxycholic ...

They found that those who lost protection also had generally higher levels of bile acids. However, those with remission had higher levels of two specific bile acids, known as lithocholates.

ursodeoxycholic acid (UDCA). The trial met its primary composite endpoint, with 51% of patients on an 80 mg dose of elafibranor achieving a cholestasis response, measured using biomarkers of liver ...

State Environmental Protection Key Laboratory of Environmental Health Impact Assessment of Emerging Contaminants, School of Environmental Science and Engineering, Shanghai Jiao Tong University, ...